Dernières nouvelles pour Innate Pharma (NASDAQ:IPHA) Stock

Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma S.A. - American Depositary Shares

Innate Pharma SA

<p>Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is preparing to release its quarterly earnings on Monday, 2025-04-28. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Teradyne to report an <strong>earnings per share</strong> (EPS) of $0.61.</p>
<p>The announcement from Teradyne is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Overview of Past Earnings</h3>
<p>Last quarter the company beat EPS by $0.04, which was followed by a 5.71% drop in the share price the next day.</p>
<p>Here's a look at Teradyne's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.91</td>
<td>0.78</td>
<td>0.77</td>
<td>0.33</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.95</td>
<td>0.90</td>
<td>0.86</td>
<td>0.51</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-11.0%</td>
<td>-13.0%</td>
<td>8.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589741_0.png" alt="eps graph" /></p>
<h3>Teradyne Share Price Analysis</h3>
<p>Shares of Teradyne were trading at $77.3 as of April 24. Over the last 52-week period, shares are down 36.34%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on Teradyne</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Teradyne.</p>
<p>Analysts have given Teradyne a total of 18 ratings, with the consensus rating being Outperform. The average one-year price target is $121.5, indicating a potential 57.18% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Entegris, Onto Innovation and Enphase Energy, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Entegris, with an average 1-year price target of $126.5, suggesting a potential 63.65% upside.</li>
<li>Analysts currently favor an Buy trajectory for Onto Innovation, with an average 1-year price target of $211.67, suggesting a potential 173.83% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Enphase Energy, with an average 1-year price target of $60.69, suggesting a potential 21.49% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Entegris, Onto Innovation and Enphase Energy, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teradyne</td>
<td>Outperform</td>
<td>12.27%</td>
<td>$447.29M</td>
<td>5.11%</td>
</tr>
<tr>
<td>Entegris</td>
<td>Buy</td>
<td>4.62%</td>
<td>$387.25M</td>
<td>2.81%</td>
</tr>
<tr>
<td>Onto Innovation</td>
<td>Buy</td>
<td>20.60%</td>
<td>$132.41M</td>
<td>2.55%</td>
</tr>
<tr>
<td>Enphase Energy</td>
<td>Neutral</td>
<td>35.22%</td>
<td>$168.24M</td>
<td>3.62%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Teradyne ranks highest in Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.</p>
<h3>Get to Know Teradyne Better</h3>
<p>Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.</p>
<h3>Key Indicators: Teradyne's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Teradyne's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>12.27%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Teradyne's net margin excels beyond industry benchmarks, reaching <strong>19.43%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.11%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Teradyne's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.91%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.03</strong>, Teradyne adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/TER/earnings"><strong>To track all earnings releases for Teradyne visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

A Look Ahead: Teradyne's Earnings Forecast

<p>Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-28. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Universal Health Servs will report an <strong>earnings per share</strong> (EPS) of $4.38.</p>
<p>The announcement from Universal Health Servs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings Track Record</h3>
<p>During the last quarter, the company reported an EPS beat by $0.74, leading to a 3.3% increase in the share price on the subsequent day.</p>
<p>Here's a look at Universal Health Servs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>4.18</td>
<td>3.70</td>
<td>3.28</td>
<td>3.16</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>4.92</td>
<td>3.71</td>
<td>4.31</td>
<td>3.70</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>3.0%</td>
<td>-10.0%</td>
<td>10.0%</td>
<td>-0.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589733_0.png" alt="eps graph" /></p>
<h3>Performance of Universal Health Servs Shares</h3>
<p>Shares of Universal Health Servs were trading at $174.0 as of April 24. Over the last 52-week period, shares are up 2.88%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Universal Health Servs</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Universal Health Servs.</p>
<p>Universal Health Servs has received a total of 7 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $219.86, the consensus suggests a potential 26.36% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Tenet Healthcare, Encompass Health and Ensign Group, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Tenet Healthcare, with an average 1-year price target of $161.0, suggesting a potential 7.47% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Encompass Health, with an average 1-year price target of $119.25, suggesting a potential 31.47% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Ensign Group, with an average 1-year price target of $160.33, suggesting a potential 7.86% downside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
<p>Within the peer analysis summary, vital metrics for Tenet Healthcare, Encompass Health and Ensign Group are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Universal Health Services</td>
<td>Neutral</td>
<td>11.08%</td>
<td>$3.71B</td>
<td>5.01%</td>
</tr>
<tr>
<td>Tenet Healthcare</td>
<td>Outperform</td>
<td>-5.71%</td>
<td>$4.14B</td>
<td>7.95%</td>
</tr>
<tr>
<td>Encompass Health</td>
<td>Outperform</td>
<td>12.69%</td>
<td>$585.90M</td>
<td>5.87%</td>
</tr>
<tr>
<td>Ensign Group</td>
<td>Outperform</td>
<td>15.49%</td>
<td>$178.91M</td>
<td>4.45%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Universal Health Services is positioned in the middle among its peers for Consensus rating. It ranks at the bottom for Revenue Growth. In terms of Gross Profit, it is at the top among its peers. For Return on Equity, it is positioned in the middle compared to its peers.</p>
<h3>Unveiling the Story Behind Universal Health Servs</h3>
<p>Universal Health Services Inc owns and operates acute care hospitals, behavior health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The firm operates in two segments: Acute Care Hospital Services and Behavioral Health Services. The company generates the majority of its revenue from the Acute Care Hospital Services segment. The Acute Care Hospital Services segment includes the firm's acute care hospitals, surgical hospitals, and surgery and oncology centers.</p>
<h3>Universal Health Servs: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Universal Health Servs displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately <strong>11.08%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Universal Health Servs's net margin excels beyond industry benchmarks, reaching <strong>8.08%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Universal Health Servs's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>5.01%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Universal Health Servs's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>2.31%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Universal Health Servs's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.74</strong>.</p>
<p><a href="https://www.benzinga.com/quote/UHS/earnings"><strong>To track all earnings releases for Universal Health Servs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


An Overview of Universal Health Servs's Earnings

<p>Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Welltower to report an <strong>earnings per share</strong> (EPS) of $1.14.</p>
<p>Welltower bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company beat EPS by $0.01, leading to a 2.16% increase in the share price the following trading session.</p>
<p>Here's a look at Welltower's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.12</td>
<td>1.04</td>
<td>1.01</td>
<td>0.94</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.13</td>
<td>1.11</td>
<td>1.05</td>
<td>1.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>2.0%</td>
<td>5.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589724_0.png" alt="eps graph" /></p>
<h3>Tracking Welltower's Stock Performance</h3>
<p>Shares of Welltower were trading at $147.75 as of April 24. Over the last 52-week period, shares are up 54.01%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Insights on Welltower</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Welltower.</p>
<p>With 9 analyst ratings, Welltower has a consensus rating of Outperform. The average one-year price target is $168.33, indicating a potential 13.93% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Ventas, Alexandria Real Estate and Healthpeak Properties, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Neutral trajectory for Ventas, with an average 1-year price target of $73.5, suggesting a potential 50.25% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Alexandria Real Estate, with an average 1-year price target of $115.0, suggesting a potential 22.17% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Healthpeak Properties, with an average 1-year price target of $23.75, suggesting a potential 83.93% downside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Ventas, Alexandria Real Estate and Healthpeak Properties, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welltower</td>
<td>Outperform</td>
<td>29.18%</td>
<td>$809.93M</td>
<td>0.39%</td>
</tr>
<tr>
<td>Ventas</td>
<td>Neutral</td>
<td>10.53%</td>
<td>$546M</td>
<td>0.55%</td>
</tr>
<tr>
<td>Alexandria Real Estate</td>
<td>Neutral</td>
<td>2.78%</td>
<td>$522.82M</td>
<td>-0.36%</td>
</tr>
<tr>
<td>Healthpeak Properties</td>
<td>Outperform</td>
<td>26.07%</td>
<td>$420.96M</td>
<td>0.05%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Welltower ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it has the lowest Return on Equity. Overall, Welltower is positioned favorably compared to its peers in terms of financial performance metrics.</p>
<h3>Unveiling the Story Behind Welltower</h3>
<p>Welltower owns a diversified healthcare portfolio of 2,271 in-place properties spread across the senior housing, medical office, and skilled nursing/postacute care sectors. The portfolio includes over 100 properties in both Canada and the United Kingdom as the company looks for additional investment opportunities in countries with mature healthcare systems that operate similarly to that of the United States.</p>
<h3>Breaking Down Welltower's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> Welltower's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>29.18%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>5.41%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Welltower's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>0.39%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.24%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Welltower's debt-to-equity ratio is below the industry average at <strong>0.52</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/WELL/earnings"><strong>To track all earnings releases for Welltower visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


WELL

Welltower's Earnings Outlook

<p>Roper Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) is gearing up to announce its quarterly earnings on Monday, 2025-04-28. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Roper Techs will report an <strong>earnings per share</strong> (EPS) of $4.75.</p>
<p>Roper Techs bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.08 in the last quarter, leading to a 0.89% increase in the share price on the following day.</p>
<p>Here's a look at Roper Techs's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>4.73</td>
<td>4.53</td>
<td>4.46</td>
<td>4.34</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>4.81</td>
<td>4.62</td>
<td>4.48</td>
<td>4.41</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-0.0%</td>
<td>2.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589712_0.png" alt="eps graph" /></p>
<h3>Market Performance of Roper Techs's Stock</h3>
<p>Shares of Roper Techs were trading at $559.66 as of April 24. Over the last 52-week period, shares are up 8.03%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Roper Techs</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Roper Techs.</p>
<p>The consensus rating for Roper Techs is Buy, based on 7 analyst ratings. With an average one-year price target of $613.29, there's a potential 9.58% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Atlassian, Autodesk and Workday, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Atlassian, with an average 1-year price target of $316.85, suggesting a potential 43.39% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Autodesk, with an average 1-year price target of $333.88, suggesting a potential 40.34% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Workday, with an average 1-year price target of $303.36, suggesting a potential 45.8% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
<p>The peer analysis summary provides a snapshot of key metrics for Atlassian, Autodesk and Workday, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Roper Techs</td>
<td>Buy</td>
<td>16.34%</td>
<td>$1.28B</td>
<td>2.47%</td>
</tr>
<tr>
<td>Atlassian</td>
<td>Outperform</td>
<td>21.35%</td>
<td>$1.06B</td>
<td>-3.40%</td>
</tr>
<tr>
<td>Autodesk</td>
<td>Outperform</td>
<td>11.57%</td>
<td>$1.49B</td>
<td>11.57%</td>
</tr>
<tr>
<td>Workday</td>
<td>Outperform</td>
<td>15.04%</td>
<td>$1.67B</td>
<td>1.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Roper Techs ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit. For Return on Equity, it is in the middle compared to its peers.</p>
<h3>Get to Know Roper Techs Better</h3>
<p>Roper Technologies is a diversified technology company that operates three segments: application software, network software, and technology enabled products. Roper acquires asset light, cash generative businesses and deploys excess cash to acquire further portfolio companies. The firm operates a highly decentralized model with portfolio company management holding autonomy and accountability for key operational decisions, and a small, centralized team overseeing capital deployment and providing executive coaching and reviewing strategic goals.</p>
<h3>Unraveling the Financial Story of Roper Techs</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Roper Techs's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of <strong>16.34%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Roper Techs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>24.63%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>2.47%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Roper Techs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>1.47%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.41</strong>, Roper Techs adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<p><a href="https://www.benzinga.com/quote/ROP/earnings"><strong>To track all earnings releases for Roper Techs visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Insights Ahead: Roper Techs's Quarterly Earnings

<p>Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) is preparing to release its quarterly earnings on Monday, 2025-04-28. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Cadence Design Sys to report an <strong>earnings per share</strong> (EPS) of $1.50.</p>
<p>The announcement from Cadence Design Sys is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.06 in the last quarter, leading to a 8.78% drop in the share price on the following day.</p>
<p>Here's a look at Cadence Design Sys's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.82</td>
<td>1.44</td>
<td>1.22</td>
<td>1.13</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.88</td>
<td>1.64</td>
<td>1.28</td>
<td>1.17</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-9.0%</td>
<td>13.0%</td>
<td>-1.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589704_0.png" alt="eps graph" /></p>
<h3>Cadence Design Sys Share Price Analysis</h3>
<p>Shares of Cadence Design Sys were trading at $281.78 as of April 24. Over the last 52-week period, shares are down 0.08%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<h3>Analyst Views on Cadence Design Sys</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Cadence Design Sys.</p>
<p>The consensus rating for Cadence Design Sys is Outperform, derived from 9 analyst ratings. An average one-year price target of $310.89 implies a potential 10.33% upside.</p>
<h3>Analyzing Ratings Among Peers</h3>
<p>In this comparison, we explore the analyst ratings and average 1-year price targets of Synopsys, AppLovin and Workday, three prominent industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Outperform trajectory for Synopsys, with an average 1-year price target of $598.5, suggesting a potential 112.4% upside.</li>
<li>Analysts currently favor an Buy trajectory for AppLovin, with an average 1-year price target of $476.4, suggesting a potential 69.07% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Workday, with an average 1-year price target of $303.36, suggesting a potential 7.66% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary offers a detailed examination of key metrics for Synopsys, AppLovin and Workday, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cadence Design Systems</td>
<td>Outperform</td>
<td>26.89%</td>
<td>$1.14B</td>
<td>7.37%</td>
</tr>
<tr>
<td>Synopsys</td>
<td>Outperform</td>
<td>-3.68%</td>
<td>$1.19B</td>
<td>3.23%</td>
</tr>
<tr>
<td>AppLovin</td>
<td>Buy</td>
<td>44.01%</td>
<td>$1.05B</td>
<td>59.04%</td>
</tr>
<tr>
<td>Workday</td>
<td>Outperform</td>
<td>15.04%</td>
<td>$1.67B</td>
<td>1.06%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Cadence Design Systems ranks highest in Revenue Growth among its peers. It also leads in Gross Profit margin. However, it has the lowest Return on Equity compared to its peers.</p>
<h3>Discovering Cadence Design Sys: A Closer Look</h3>
<p>Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates and aids in the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enables system-level analysis and verification solutions.</p>
<h3>Understanding the Numbers: Cadence Design Sys's Finances</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Cadence Design Sys's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>26.89%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.</p>
<p><strong>Net Margin:</strong> Cadence Design Sys's net margin excels beyond industry benchmarks, reaching <strong>25.09%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Cadence Design Sys's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.37%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.75%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Cadence Design Sys's debt-to-equity ratio surpasses industry norms, standing at <strong>0.55</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/CDNS/earnings"><strong>To track all earnings releases for Cadence Design Sys visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CDNS

Exploring Cadence Design Sys's Earnings Expectations

<p>Financial giants have made a conspicuous bullish move on NVIDIA. Our analysis of options history for NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) revealed 11 unusual trades.</p>
<p>Delving into the details, we found 63% of traders were bullish, while 18% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $260,477, and 6 were calls, valued at $197,652.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $105.0 to $140.0 for NVIDIA over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for NVIDIA's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NVIDIA's whale activity within a strike price range from $105.0 to $140.0 in the last 30 days. </p>
<h3>NVIDIA Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589686_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NVDA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$1.01</td>
<td>$1.0</td>
<td>$1.0</td>
<td>$107.00</td>
<td>$81.2K</td>
<td>3.9K</td>
<td>12.4K</td>
</tr>
<tr>
<td>NVDA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/02/25</td>
<td>$2.36</td>
<td>$2.35</td>
<td>$2.35</td>
<td>$105.00</td>
<td>$60.1K</td>
<td>20.7K</td>
<td>7.1K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/25/25</td>
<td>$0.88</td>
<td>$0.86</td>
<td>$0.91</td>
<td>$107.00</td>
<td>$46.2K</td>
<td>75.0K</td>
<td>38.2K</td>
</tr>
<tr>
<td>NVDA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/25/25</td>
<td>$0.46</td>
<td>$0.44</td>
<td>$0.45</td>
<td>$106.00</td>
<td>$44.8K</td>
<td>13.0K</td>
<td>27.4K</td>
</tr>
<tr>
<td>NVDA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/02/25</td>
<td>$3.05</td>
<td>$2.99</td>
<td>$2.99</td>
<td>$107.00</td>
<td>$43.1K</td>
<td>8.3K</td>
<td>3.4K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NVIDIA</h3>
<p>Nvidia is a leading developer of graphics processing units. Traditionally, GPUs were used to enhance the experience on computing platforms, most notably in gaming applications on PCs. GPU use cases have since emerged as important semiconductors used in artificial intelligence. Nvidia not only offers AI GPUs, but also a software platform, Cuda, used for AI model development and training. Nvidia is also expanding its data center networking solutions, helping to tie GPUs together to handle complex workloads.</p>
<p>Following our analysis of the options activities associated with NVIDIA, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of NVIDIA</h3>
<ul>
<li>Currently trading with a volume of 26,342,948, the NVDA's price is up by 0.7%, now at $107.17. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 26 days.</li>
</ul>
<h3>What Analysts Are Saying About NVIDIA</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $155.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on NVIDIA, which currently sits at a price target of $150.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on NVIDIA, which currently sits at a price target of $180.<br />
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $175.<br />
&#x2A; Consistent in their evaluation, an analyst from DA Davidson keeps a Neutral rating on NVIDIA with a target price of $120.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Buy rating for NVIDIA, targeting a price of $150. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NVIDIA, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

NVDA

Spotlight on NVIDIA: Analyzing the Surge in Options Activity

Macro Economic Events

News

Econ #s

Economics

Michigan Consumer Expectations For April 47.3 Vs  47.2 Est.; 52.6 Prior

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Taiwan Semiconductor</strong>.</p>
<p>Looking at options history for Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) we detected 9 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 44% of the investors opened trades with bullish expectations and 33% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $134,220 and 6, calls, for a total amount of $1,498,550.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $148.0 to $190.0 for Taiwan Semiconductor over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Taiwan Semiconductor's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Taiwan Semiconductor's whale activity within a strike price range from $148.0 to $190.0 in the last 30 days. </p>
<h3>Taiwan Semiconductor 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589681_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.6</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$170.00</td>
<td>$1.1M</td>
<td>8.8K</td>
<td>113</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/09/25</td>
<td>$2.9</td>
<td>$2.88</td>
<td>$2.9</td>
<td>$167.50</td>
<td>$145.0K</td>
<td>2.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.6</td>
<td>$6.45</td>
<td>$6.5</td>
<td>$170.00</td>
<td>$65.0K</td>
<td>8.8K</td>
<td>113</td>
</tr>
<tr>
<td>TSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$25.75</td>
<td>$25.2</td>
<td>$25.5</td>
<td>$170.00</td>
<td>$51.0K</td>
<td>263</td>
<td>20</td>
</tr>
<tr>
<td>TSM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.95</td>
<td>$1.93</td>
<td>$1.93</td>
<td>$148.00</td>
<td>$46.3K</td>
<td>243</td>
<td>319</td>
</tr>
</tbody>
</table>
</p>
<h3>About Taiwan Semiconductor</h3>
<p>Taiwan Semiconductor Manufacturing Co. is the world's largest dedicated chip foundry, with mid-60s market share in 2024. TSMC was founded in 1987 as a joint venture of Philips, the government of Taiwan, and private investors. It went public in Taiwan in 1994 and as an ADR in the US in 1997. TSMC's scale and high-quality technology allow the firm to generate solid operating margins, even in the highly competitive foundry business. Furthermore, the shift to the fabless business model has created tailwinds for TSMC. The foundry leader has an illustrious customer base, including Apple, AMD, and Nvidia, that looks to apply cutting-edge process technologies to its semiconductor designs. TSMC employs more than 73,000 people.</p>
<p>After a thorough review of the options trading surrounding Taiwan Semiconductor, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Taiwan Semiconductor</h3>
<ul>
<li>Trading volume stands at 1,721,877, with TSM's price down by -1.21%, positioned at $162.2.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Taiwan Semiconductor</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $230.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Taiwan Semiconductor, targeting a price of $215.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on Taiwan Semiconductor, maintaining a target price of $250.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $225.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Taiwan Semiconductor options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Unpacking the Latest Options Trading Trends in Taiwan Semiconductor

<p>Throughout the last three months, 4 analysts have evaluated PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $84.75, along with a high estimate of $95.00 and a low estimate of $70.00. Highlighting a 16.09% decrease, the current average has fallen from the previous average price target of $101.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589660_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of PROCEPT BioRobotics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Craig Bijou         &#x7C;B of A Securities   &#x7C;Lowers         &#x7C;Buy            &#x7C;              $84.00&#x7C;$104.00             &#x7C;<br />
&#x7C;Richard Newitter    &#x7C;Truist Securities   &#x7C;Lowers         &#x7C;Buy            &#x7C;              $70.00&#x7C;$90.00              &#x7C;<br />
&#x7C;Patrick Wood        &#x7C;Morgan Stanley      &#x7C;Lowers         &#x7C;Overweight     &#x7C;              $95.00&#x7C;$105.00             &#x7C;<br />
&#x7C;Richard Newitter    &#x7C;Truist Securities   &#x7C;Lowers         &#x7C;Buy            &#x7C;              $90.00&#x7C;$105.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to PROCEPT BioRobotics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PROCEPT BioRobotics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of PROCEPT BioRobotics's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of PROCEPT BioRobotics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PRCT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on PROCEPT BioRobotics analyst ratings.</strong></a></p>
<h2>Discovering PROCEPT BioRobotics: A Closer Look</h2>
<p>PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.</p>
<h3>Financial Milestones: PROCEPT BioRobotics's Journey</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> PROCEPT BioRobotics's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>56.57%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> PROCEPT BioRobotics's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-27.63%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> PROCEPT BioRobotics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-5.86%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> PROCEPT BioRobotics's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-4.15%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> PROCEPT BioRobotics's debt-to-equity ratio is below the industry average. With a ratio of <b>0.2</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

PRCT

Where PROCEPT BioRobotics Stands With Analysts

<p>Citigroup  analyst Ygal Arounian   maintains Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) with a Neutral and lowers the price target from $34 to $31.</p>


Price Target

MTCH

Citigroup Maintains Neutral on Match Group, Lowers Price Target to $31

<p>Analysts' ratings for Betterware de Mexico SAPI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWMX#NYSE">BWMX</a>) over the last quarter vary from bullish to bearish, as provided by 8 analysts.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $22.5, a high estimate of $22.50, and a low estimate of $22.50. This current average is unchanged from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589652_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Betterware de Mexico SAPI. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;       Analyst Firm        &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;---------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;              $22.50&#x7C;$22.50              &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Betterware de Mexico SAPI. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Betterware de Mexico SAPI compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Betterware de Mexico SAPI's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Betterware de Mexico SAPI's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BWMX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Betterware de Mexico SAPI analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Betterware de Mexico SAPI: A Closer Look</h2>
<p>Betterware de Mexico SAPI de CV is a direct-to-consumer selling company. The company operates through two business segments: the home organization products (Betterware segment or BWM segment) and the beauty and personal care products (B and PC) (JAFRA segment). The Betterware's segment is divided into different categories based on the type of products it sells and includes, kitchen and food preservation, home solutions, bathroom, laundry &amp; cleaning, tech and mobility, and bedroom and wellness products. The JAFRA's segment is divided into fragrance, color, skincare, and toiletries products. The company generates a majority of its revenue from the Beauty and personal care (B&amp;PC) (JAFRA segment). Geographically, key revenue for the company is derived from Mexico.</p>
<h3>Betterware de Mexico SAPI: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3M period, Betterware de Mexico SAPI showcased positive performance, achieving a revenue growth rate of <strong>13.45%</strong> as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Betterware de Mexico SAPI's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.96%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Betterware de Mexico SAPI's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>19.19%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Betterware de Mexico SAPI's ROA excels beyond industry benchmarks, reaching <strong>2.11%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Betterware de Mexico SAPI's debt-to-equity ratio surpasses industry norms, standing at <strong>4.44</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


BWMX

Beyond The Numbers: 8 Analysts Discuss Betterware de Mexico SAPI Stock

Michigan 5-Year Inflation Expectations (Apr) 4.4% vs 4.4% EST; Prior 4.1%

<p>In the latest quarter, 10 analysts provided ratings for Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $51.3, a high estimate of $68.00, and a low estimate of $39.00. A decline of 3.02% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589640_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Criteo among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Ygal Arounian       &#x7C;Citigroup           &#x7C;Lowers         &#x7C;Buy            &#x7C;              $47.00&#x7C;$60.00              &#x7C;<br />
&#x7C;John Egbert         &#x7C;Stifel              &#x7C;Lowers         &#x7C;Buy            &#x7C;              $46.00&#x7C;$61.00              &#x7C;<br />
&#x7C;Brian Nowak         &#x7C;Morgan Stanley      &#x7C;Lowers         &#x7C;Equal-Weight   &#x7C;              $40.00&#x7C;$44.00              &#x7C;<br />
&#x7C;Doug Anmuth         &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Neutral        &#x7C;              $39.00&#x7C;$48.00              &#x7C;<br />
&#x7C;John Egbert         &#x7C;Stifel              &#x7C;Raises         &#x7C;Buy            &#x7C;              $61.00&#x7C;$59.00              &#x7C;<br />
&#x7C;Alec Brondolo       &#x7C;Wells Fargo         &#x7C;Raises         &#x7C;Overweight     &#x7C;              $68.00&#x7C;$63.00              &#x7C;<br />
&#x7C;Brian Nowak         &#x7C;Morgan Stanley      &#x7C;Raises         &#x7C;Equal-Weight   &#x7C;              $44.00&#x7C;$42.00              &#x7C;<br />
&#x7C;Brian Pitz          &#x7C;BMO Capital         &#x7C;Raises         &#x7C;Outperform     &#x7C;              $60.00&#x7C;$48.00              &#x7C;<br />
&#x7C;Tom White           &#x7C;DA Davidson         &#x7C;Raises         &#x7C;Buy            &#x7C;              $57.00&#x7C;$53.00              &#x7C;<br />
&#x7C;Mark Zgutowicz      &#x7C;Benchmark           &#x7C;Maintains      &#x7C;Buy            &#x7C;              $51.00&#x7C;$51.00              &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Criteo. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Criteo compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Criteo's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Criteo's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRTO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Criteo analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Criteo</h2>
<p>Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.</p>
<h3>Criteo: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Criteo faced challenges, resulting in a decline of approximately <strong>-2.34%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Criteo's net margin excels beyond industry benchmarks, reaching <strong>12.86%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Criteo's ROE excels beyond industry benchmarks, reaching <strong>6.77%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Criteo's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.18%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Criteo's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.1</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CRTO

Forecasting The Future: 10 Analyst Projections For Criteo

<p>Across the recent three months, 6 analysts have shared their insights on Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $173.0, a high estimate of $185.00, and a low estimate of $164.00. Highlighting a 0.86% decrease, the current average has fallen from the previous average price target of $174.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589631_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Procter &amp; Gamble is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;    Analyst Firm    &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Olivia Tong         &#x7C;B of A Securities   &#x7C;Lowers         &#x7C;Buy            &#x7C;             $180.00&#x7C;$190.00             &#x7C;<br />
&#x7C;Nik Modi            &#x7C;RBC Capital         &#x7C;Maintains      &#x7C;Sector Perform &#x7C;             $164.00&#x7C;$164.00             &#x7C;<br />
&#x7C;Andrea Teixeira     &#x7C;JP Morgan           &#x7C;Lowers         &#x7C;Overweight     &#x7C;             $172.00&#x7C;$181.00             &#x7C;<br />
&#x7C;Bill Chappell       &#x7C;Truist Securities   &#x7C;Raises         &#x7C;Buy            &#x7C;             $185.00&#x7C;$180.00             &#x7C;<br />
&#x7C;Lauren Lieberman    &#x7C;Barclays            &#x7C;Raises         &#x7C;Equal-Weight   &#x7C;             $165.00&#x7C;$159.00             &#x7C;<br />
&#x7C;Korinne Wolfmeyer   &#x7C;Piper Sandler       &#x7C;Lowers         &#x7C;Neutral        &#x7C;             $172.00&#x7C;$173.00             &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Procter &amp; Gamble. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Procter &amp; Gamble compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Procter &amp; Gamble's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Procter &amp; Gamble's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PG/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Procter &amp; Gamble analyst ratings.</strong></a></p>
<h2>All You Need to Know About Procter &amp; Gamble</h2>
<p>Since its founding in 1837, Procter &amp; Gamble has become one of the world's largest consumer product manufacturers, with annual sales approaching $85 billion. It operates with a lineup of leading brands, including more than 20 that generate north of $1 billion each in annual global sales, such as Tide laundry detergent, Charmin toilet paper, Pantene shampoo, and Pampers diapers. Sales outside its home turf represent more than half of the firm's consolidated total.</p>
<h3>Understanding the Numbers: Procter &amp; Gamble's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Procter &amp; Gamble's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately <strong>2.06%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Procter &amp; Gamble's net margin excels beyond industry benchmarks, reaching <strong>20.83%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>8.99%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Procter &amp; Gamble's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.66%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.69</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


6 Analysts Have This To Say About Procter & Gamble

<p><strong>Tradeweb Markets's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TW#NYSE">TW</a>) short percent of float has risen 16.78% since its last report. The company recently reported that it has <strong>2.03 million shares sold short</strong>, which is 1.74% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.9 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Tradeweb Markets Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589630_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Tradeweb Markets has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Tradeweb Markets's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Tradeweb Markets's peer group average for short interest as a percentage of float is 3.50%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Trading Ideas

What's Driving the Market Sentiment Around Tradeweb Markets?

<p><strong>Prosperity Bancshares's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PB#NYSE">PB</a>) short percent of float has fallen 18.87% since its last report. The company recently reported that it has <strong>1.40 million shares sold short</strong>, which is 1.72% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.28 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Prosperity Bancshares Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589625_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Prosperity Bancshares has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Prosperity Bancshares's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Prosperity Bancshares's peer group average for short interest as a percentage of float is 3.73%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Do Investors Really Feel About Prosperity Bancshares?

<p>In the preceding three months, 5 analysts have released ratings for Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.6, a high estimate of $6.00, and a low estimate of $4.00. This current average represents a 6.67% decrease from the previous average price target of $6.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589624_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Vince Holding. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<p>&#x7C;      Analyst       &#x7C;       Analyst Firm        &#x7C; Action Taken  &#x7C;    Rating     &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C;<br />
&#x7C;--------------------&#x7C;---------------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Lowers         &#x7C;Buy            &#x7C;               $4.00&#x7C;$6.00               &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;               $6.00&#x7C;$6.00               &#x7C;<br />
&#x7C;Eric Berg           &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;               $6.00&#x7C;$6.00               &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;               $6.00&#x7C;$6.00               &#x7C;<br />
&#x7C;Eric Beder          &#x7C;Small Cap Consumer Research&#x7C;Maintains      &#x7C;Buy            &#x7C;               $6.00&#x7C;$6.00               &#x7C;</p>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vince Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vince Holding compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Vince Holding's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Vince Holding's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VNCE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vince Holding analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Delving into Vince Holding's Background</h2>
<p>Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.</p>
<h3>Financial Milestones: Vince Holding's Journey</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3M period, Vince Holding faced challenges, resulting in a decline of approximately <strong>-4.66%</strong> in revenue growth as of 31 October, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Vince Holding's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>5.43%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Vince Holding's ROE excels beyond industry benchmarks, reaching <strong>7.94%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Vince Holding's ROA excels beyond industry benchmarks, reaching <strong>1.71%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>2.63</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VNCE

Vince Holding Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

<p>Looking into the current session, <strong>AutoZone Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>)</strong> shares are trading at $3586.20, after a <strong>0.65%</strong> decrease. Over the past month, the stock decreased by <strong>4.90%</strong>, but over the past year, it actually went up by <strong>19.59%</strong>. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745589619_0_0.png" alt="Past Year Chart" /></p>

<h3>Comparing AutoZone P/E Against Its Peers</h3>
<p>The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. </p>
<p>AutoZone has a lower P/E than the aggregate P/E of <strong>26.19</strong> of the Specialty Retail industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. </p>
<p>
</p><p><img src="https://www.benzinga.com/files/images/story/2025/1745589619_1.png" alt="Guage" /></p>

<p>In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes. </p>


Intraday Update

A Look Into AutoZone Inc's Price Over Earnings

Michigan 1-Year Inflation Expectations For April 6.5% vs 6.7% EST; Vs 5.0% Prior

<p><strong>Westinghouse Air Brake's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) short percent of float has fallen 28.07% since its last report. The company recently reported that it has <strong>1.83 million shares sold short</strong>, which is 1.23% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.66 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Westinghouse Air Brake Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1745589619_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Westinghouse Air Brake has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Westinghouse Air Brake's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Westinghouse Air Brake's peer group average for short interest as a percentage of float is 6.19%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Comments

Innate Pharma

Actualités

Dernières nouvelles pour Innate Pharma (NASDAQ:IPHA) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL